Heart Failure

Meet the patient

A 68-year-old man arrives breathless, having slept upright in a chair for the last week. He has bibasal crackles to mid-zones, a raised JVP, a displaced apex, and a third heart sound you can hear with the bell. He cannot finish a sentence without stopping for breath.^[1]

Three questions decide his next 48 hours: what is his ejection fraction? (the echo, because it picks the drug pathway), is he wet or dry, warm or cold? (the bedside, because it picks the immediate therapy), and what tipped him over? (the history, because every decompensation has a precipitant you must find and fix). Hold those three and the four pillars fall into place.^[1]

What heart failure is — and the two things it is not

Heart failure is a clinical syndrome, not a single disease. It needs three things together: typical symptoms (breathlessness, fatigue, ankle swelling), typical signs (raised JVP, pulmonary crackles, oedema), and objective evidence of a structural or functional cardiac abnormality — usually a reduced or preserved ejection fraction on echo, or a raised natriuretic peptide.^[1]

It is not a single mechanical fault. The heart fails one of two ways: it cannot contract forcefully enough to eject (systolic or pump failure), or it cannot relax and fill at normal pressures (diastolic or filling failure). Most patients have elements of both by the time they present.^[1]

And it is not a disease diuretics can fix. The defining problem is that cardiac output falls short of demand, which trips off compensatory neurohormonal cascades — RAAS, sympathetic, vasopressin — that initially help but chronically remodel and destroy the myocardium. Relieving symptoms with a loop diuretic does nothing to the natural history; the four pillars each interrupt one of those harmful axes. That is the whole intellectual case for modern heart-failure therapy in one sentence.^[1]

The ejection-fraction split — the single most important classification

The EF split decides which disease-modifying drugs work and which do not, so it is the first question on every heart-failure echo report:^[1][2]

^[1]

The split is mechanistic, which is why it earns marks. HFrEF is a disease of impaired contractility driven by neurohormonal activation, so blocking RAAS, sympathetic overdrive, and the SGLT2 pathway changes the disease course. HFpEF is fundamentally different — a stiff, poorly relaxing ventricle in a systemically inflamed, comorbid patient — and the HFrEF toolkit largely fails in it, with the single exception of SGLT2 inhibitors, which work across the whole EF spectrum.^[1]

Two classifications on top of the EF — and why they are not the same axis

The NYHA class grades how the patient feels right now. It is subjective, it can move in either direction with treatment or decompensation, and you reassess it at every visit:^[1]

^{[1] [1]}

A few more axes complete the picture: by temporal pattern — new-onset, acute decompensation of chronic (most admissions), and end-stage; by clinical picture — congestive (volume overload dominant) versus low-output (underperfusion dominant); and by chamber — left-sided (pulmonary congestion), right-sided (systemic congestion), or biventricular, though most patients have both circuits involved by the time they present.^[1]

How common, how lethal, and what tips a patient over

Heart failure is a disease of ageing populations: in developed countries the prevalence of known heart failure is 1 to 2 percent of the general adult population, and in community-dwelling people aged 60 and over an echocardiography-based systematic review found a median prevalence of 11.8 percent.^[31][32] Survival from MI has improved, populations are ageing, so the prevalence is growing. Despite modern therapy it remains life-limiting — a meta-analysis of over 1.5 million patients put survival at 87 percent at one year and 57 percent at five years, and in India's Trivandrum Heart Failure Registry 59 percent of patients admitted with heart failure had died by five years (median survival 3.1 years). An HF hospitalisation is itself one of the strongest prognostic markers in all of cardiology.^[31][29]

^{[31] [32] [33] [30] [29] [28]}

The leading underlying causes differ by EF group. In HFrEF, ischaemic heart disease is the single commonest cause — 52 percent of SCD-HeFT participants, and 72 percent of heart-failure admissions in the Trivandrum Heart Failure Registry in India — followed by hypertension, dilated cardiomyopathy, and valvular disease.^[33][30] In HFpEF the drivers are hypertension, diabetes, obesity, atrial fibrillation, and age — the typical HFpEF patient is an elderly, hypertensive, diabetic woman, because those are exactly the conditions that stiffen a ventricle over decades.^[1]

The precipitants of acute decompensation are a distinct, high-yield list — finding and treating the precipitant is as important as decongesting the patient. The FAILURE mnemonic:^[1]

^{[1] [34]}

A prior HF hospitalisation is itself a powerful prognostic marker — it predicts further admissions and death, not an isolated bad event. Each admission is a step down the long-term trajectory.^[1]

Why the heart fails — the neurohormonal model

Heart failure begins with a failing pump — reduced cardiac output from impaired contractility (HFrEF) or impaired filling at acceptable pressures (HFpEF). The body reads the falling output as underperfusion and mounts a compensatory neurohormonal response along four axes: RAAS, the sympathetic nervous system, arginine vasopressin (ADH), and the counter-regulatory natriuretic peptides.^[1]

Enlarge

RAAS. Falling renal perfusion releases renin, which makes angiotensin I, which ACE converts to angiotensin II — a vasoconstrictor (raises afterload) that drives aldosterone (sodium and water retention, potassium loss), promotes ADH release, and is directly cardiotoxic through myocyte hypertrophy and fibrosis. Aldosterone itself, independently of angiotensin II, causes myocardial fibrosis — which is exactly why the MRA earns its pillar.^[1]

The sympathetic nervous system. Baroreceptor-driven catecholamine discharge initially supports stroke volume and heart rate — the rationale for the old, abandoned "inotrope-first" approach — but chronically it is directly cardiotoxic: myocyte apoptosis, arrhythmia, higher myocardial oxygen demand, beta-1 receptor downregulation, accelerated remodelling. Plasma noradrenaline tracks with mortality.^[1]

Vasopressin and the natriuretic peptides. ADH rises by non-osmotic release, driving free-water reabsorption through V2 receptors — the mechanism behind the dilutional hyponatraemia of advanced disease and a marker of poor prognosis. Against all this, ANP (atria) and BNP (ventricles) promote natriuresis and counter-regulate RAAS and sympathetic activity; in chronic HF they are ultimately overwhelmed, and their measurement is the basis of the diagnostic biomarker.^[1]

Cardiac remodelling is the structural signature of chronic neurohormonal injury: myocyte hypertrophy and elongation, interstitial fibrosis, chamber dilation (HFrEF) or wall thickening with reduced compliance (HFpEF). Remodelling is reversible, and reverse remodelling — shrinking chamber size, recovering function — is the therapeutic goal and tracks with better outcomes. The two ventricles share a septum and a pericardium, so failure in one soon compromises the other (ventricular interdependence).^[1]

How the four pillars map onto the model

Each pillar of HFrEF therapy exists to interrupt a specific maladaptive axis — which is why all four are started rather than one substituted for another:^[1]

^[1]

Enlarge

The SGLT2 inhibitor mechanism in HF is independent of glucose-lowering and probably combines mild proximal diuresis (lowering preload), improved myocardial energetics (ketone body utilisation), reduced inflammation, and lower blood pressure.^[8][9]

HFpEF is fundamentally different. The ventricle is stiff and non-compliant with impaired active relaxation and raised filling pressures; symptoms arise because the left atrium must generate high pressures to fill a stiff ventricle, transmitting back to the pulmonary veins. The driver is multi-system comorbidity — obesity, diabetes, hypertension, CKD — producing systemic microvascular inflammation and fibrosis. The RAAS and sympathetic axes were never the problem, so drugs built to interrupt them largely fail here.^[1]

The symptoms — read which circulation is congested

The symptom cluster reflects which circulation is congested and how far forward flow has fallen:^[1]

• Exertional dyspnoea — the earliest and commonest symptom; cardiac output cannot rise with exertion.
• Orthopnoea — breathlessness within minutes of lying flat. Recumbency shifts splanchnic and leg volume into the central circulation, raising pulmonary venous pressure. Relief on sitting up (or extra pillows) is the defining feature; two-pillow orthopnoea suggests moderate disease.
• Paroxysmal nocturnal dyspnoea (PND) — waking gasping 1 to 2 hours after sleep. Recumbency reabsorbs interstitial oedema faster than a failing LV can clear it; the patient sits up and may seek fresh air. PND usually means more advanced disease than orthopnoea alone.
• Fatigue and effort intolerance — low cardiac output.
• Ankle swelling and abdominal fullness — right-sided congestion; ascites and hepatic congestion give bloating, anorexia, right-upper-quadrant ache.
• Nocturia — renal perfusion improves when the patient lies down, so excretion shifts to the night.
• Cachexia and muscle wasting — advanced, end-stage HF; the cardiac cachexia syndrome carries a poor prognosis.^[1]

The signs — and the S3-versus-S4 discriminator

The sign inventory on focused cardiovascular and respiratory examination:^[1]

• Elevated JVP — the single most reliable bedside marker of volume overload and right-heart congestion.
• Displaced apex beat — laterally displaced and diffuse in a dilated LV (HFrEF); sustained and heaving in a hypertrophied LV (HFpEF or pressure overload).
• Third heart sound (S3 gallop) — the auscultatory hallmark of systolic or HFrEF: low-pitched, just after S2, from rapid filling of a non-compliant or volume-overloaded ventricle.
• Fourth heart sound (S4) — more typical of diastolic dysfunction or HFpEF, produced by atrial contraction into a stiff ventricle.
• Bibasal fine crackles — pulmonary oedema (may be absent if decongested, or in chronic HF with lymphatic compensation).
• Pleural effusion — usually bilateral, right larger than left (greater pleural surface area on the right).
• Hepatomegaly, ascites, dependent and sacral oedema — right-sided congestion.
• Tachycardia, cool peripheries, narrow pulse pressure, low systolic BP — low-output or advanced HF.
• Pulsus alternans — alternating strong and weak pulses in advanced LV failure.^[1]

The one-line discriminator: an S3 means systolic failure (HFrEF); an S4 means diastolic (HFpEF). Examiners reach for it.^[1]

Left-sided signs (dyspnoea, orthopnoea, PND, crackles, effusion) reflect pulmonary venous congestion behind a failing LV. Right-sided signs (raised JVP, hepatomegaly, oedema, ascites) reflect systemic venous congestion behind a failing RV. By the time most patients present they have biventricular failure — isolated left HF tends to progress to right HF as pulmonary pressures rise. And the atypical presentations are deliberately tested: the elderly patient with confusion, falls, fatigue, or anorexia rather than classical dyspnoea; the diabetic with a relatively silent course from autonomic neuropathy.^[1]

The differential — discriminators, not a list

The differential of breathlessness and oedema is broad. Each competitor is separated on specific grounds, and examiners want the distinguishing feature, not just a name:^[1]

^[1]

A normal BNP or NT-proBNP with a normal echocardiogram is decisive in excluding a cardiac cause of dyspnoea — the negative predictive value is very high. HFpEF specifically must be separated from other causes of dyspnoea with a preserved EF (obesity, deconditioning, primary lung disease, anaemia, chronic thromboembolic disease); the clinical picture, the natriuretic peptide, and diastolic function on echo (the E-to-e-prime ratio, left atrial size) together make the call, formalised by the HFA-PEFF and H2FPEF scores.^[1]

The bedside round — JVP, apex, and the perfusion exam

The JVP is the single most useful bedside sign in heart failure. Measure it with the patient reclined at 45 degrees, using the internal jugular (not the carotid — the JVP is biphasic, non-pulsatile, occlusible, and varies with respiration). The vertical height above the sternal angle is read in centimetres of water; more than 3 cm above the sternal angle is elevated, and an elevated JVP is the most specific bedside sign of right-sided volume overload and tracks with prognosis. The hepatojugular reflux — sustained firm pressure over the liver for 15 to 30 seconds producing a JVP rise over 4 cm — means the right heart cannot accommodate the venous return.^[1]

The apex beat tells you about the LV: 5th intercostal space, mid-clavicular line is normal; lateral displacement means a dilated LV; a hyperdynamic volume-loaded apex suggests severe regurgitation; a sustained heaving apex means pressure overload, hypertrophy, or HFpEF.^[1]

Auscultate specifically for an S3 (low-pitched, just after S2, best at the apex with the bell in the left lateral position; the hallmark of systolic HF), an S4 (before S1; a stiff non-compliant ventricle — HFpEF or hypertension), a gallop rhythm (tachycardia plus S3), and murmurs of underlying valvular disease (aortic stenosis, mitral regurgitation) which may be the cause rather than the consequence. Bibasal crackles suggest pulmonary oedema, though chronic HF patients may have clear lungs thanks to lymphatic compensation.^[1]

Then assess perfusion — blood pressure, peripheral temperature, capillary refill, urine output, mentation — to gauge end-organ perfusion and the boundary with cardiogenic shock. A narrow pulse pressure, cool peripheries, and oliguria signal a low-output state that may need inotropes, not more diuresis.^[1]

Investigations — echo is pivotal, BNP rules out

First-line investigations are the echocardiogram, natriuretic peptides, a 12-lead ECG, a chest X-ray, and a blood panel (U&E, eGFR, FBC, LFT, TFT, ferritin, fasting glucose or HbA1c, lipid profile, urinalysis).^[1]

BNP and NT-proBNP are powerful rule-out tests — a normal level makes HF highly unlikely. The threshold depends on the setting: NICE uses natriuretic peptides to rule out new acute heart failure (CG187), and NT-proBNP to trigger and prioritise echocardiography in suspected chronic heart failure (NG106):^[37][36]

^{[37] [36]}

The classic trap: BNP is degraded by neprilysin, so a patient on an ARNI (sacubitril-valsartan) has a falsely elevated BNP — use NT-proBNP in ARNI-treated patients. Both peptides rise with anything that stretches the heart (AF, PE, RV failure, renal failure, sepsis) and fall with obesity, so interpret them in context.^[1]

The echocardiogram is the single most informative investigation in HF. It measures the ejection fraction (the basis of the HFrEF, HFmrEF, HFpEF split), chamber size and wall thickness (dilated LV in HFrEF; concentric LVH in HFpEF), diastolic function (the E-to-e-prime ratio — NICE counts a ratio above 11 among its HFpEF criteria, alongside a left atrial volume index above 34 mL/m² in sinus rhythm and a wall thickness above 12 mm), valvular structure and function, right ventricular size and function and estimated RVSP, regional wall-motion abnormalities suggesting ischaemia, and pericardial effusion or thrombus.^[1][36]

The chest X-ray reads heart failure as a sequence of increasing severity: cardiomegaly (cardiothoracic ratio over 0.5), upper-lobe blood diversion (cephalisation), Kerley B lines (short horizontal basal opacities — interstitial oedema), perihilar bat-wing alveolar oedema (frank alveolar flooding, a late sign), and pleural effusions (usually bilateral, right often larger).^[1]

The ECG is abnormal in the great majority of HF patients — a completely normal ECG makes HF unlikely. Look for prior Q-wave or ischaemic changes (aetiology), LV hypertrophy with strain (hypertensive or HFpEF), left bundle branch block (relevant for CRT), atrial fibrillation (precipitant or consequence), and arrhythmia or conduction disease.^[1]

Second-line and aetiology-defining tests: coronary angiography when an ischaemic aetiology needs defining; cardiac MRI (the gold standard for tissue characterisation — infiltrative amyloid or sarcoid, inflammatory myocarditis, hypertrophic and arrhythmogenic cardiomyopathies, precise LV and RV volumes); cardiopulmonary exercise testing (peak VO2 for transplant and LVAD candidacy); iron studies (iron deficiency is common, worsens symptoms, and is treated with intravenous iron regardless of anaemia); and troponin, D-dimer, HIV and hepatitis serology, autoimmune screen, and 24-hour urine catecholamines or metanephrines where specific aetiologies are plausible.^[1]

Acute pulmonary oedema — the first ten minutes

Enlarge

Acute pulmonary oedema with respiratory distress is a medical emergency. The first ten minutes follow a familiar bundle:^[1]

^{[1] [15] [16]}

Oxygen is given to correct hypoxia; in the breathless but not hypoxic patient, non-invasive ventilation is the more effective intervention. Morphine (2.5 to 5 mg IV) was once routine for distress and preload reduction but NICE now advises against routinely offering opiates in acute heart failure — in an analysis of over 147,000 hospitalisations from the ADHERE registry, patients given morphine were more likely to require mechanical ventilation (15.4 vs 2.8 percent), be admitted to intensive care, stay longer, and die (13.0 vs 2.4 percent), and morphine remained an independent predictor of mortality after risk adjustment (OR 4.84). CPAP or BiPAP is indicated for cardiogenic pulmonary oedema with ongoing respiratory distress — in meta-analysis CPAP cut both intubation (22 percent absolute risk reduction) and mortality (13 percent absolute risk reduction) against standard therapy, while BiPAP cut intubation (18 percent) without a significant mortality reduction and showed no advantage over CPAP, so CPAP is the default first-line modality.^{[1][37][14][15]}

Cardiogenic shock — not more diuretic

Cardiogenic shock is hypotension (systolic BP under 90 mmHg) with signs of hypoperfusion — cold clammy skin, oliguria, confusion, lactic acidosis — due to a primary cardiac cause. The principles are the opposite of pulmonary oedema: this patient needs inotropic or vasopressor support and cause-directed therapy, not more diuretic. Inotropes include dobutamine (beta-1 agonist; 2 to 20 microgram/kg/min) and milrinone (a phosphodiesterase-3 inhibitor, an "inodilator"); add a vasopressor such as noradrenaline if vasodilatory shock dominates. Cause-directed therapy is essential — urgent reperfusion for an ischaemic cause, valve intervention for a mechanical catastrophe, and mechanical circulatory support for the refractory case.^[1]

The four pillars of HFrEF — name the drug, the dose, the trial

For HFrEF, guideline-directed medical therapy rests on four foundational drug classes, each with an independent mortality benefit from a landmark trial. Where tolerated, all four are now started together (sequenced by tolerability rather than one class fully titrated before the next begins) at low dose and uptitrated to target over weeks.^[1]

Pillar 1 — RAAS blockade: ARNI or ACE-inhibitor

The angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril-valsartan is preferred over an ACE-inhibitor on the strength of PARADIGM-HF, in which sacubitril-valsartan (LCZ696) 200 mg twice daily reduced cardiovascular death and HF hospitalisation versus enalapril.^[4] If an ACE-inhibitor is used instead, enalapril — the agent that proved the class in severe HF (CONSENSUS, dosed 2.5 to 40 mg per day with a 40 percent mortality reduction at six months)^[3] and in symptomatic LV dysfunction (SOLVD, 2.5 to 20 mg per day)^[22] — or ramipril, whose post-infarction HF regimen improved survival (AIRE). The starting dose for sacubitril-valsartan is 49/51 mg twice daily (24/26 mg twice daily if coming off a low-dose ACE-inhibitor), uptitrated to the 97/103 mg twice daily target.^[1]

The classic trap: switching from an ACE-inhibitor to ARNI needs a 36-hour washout to prevent angioedema (neprilysin inhibition plus ACE inhibition accumulates bradykinin). An ARB can switch across more directly.^[1]

Pillar 2 — Beta-blocker

One of the four beta-blockers proven in HF — bisoprolol, titrated in CIBIS-II from 1.25 mg up to a maximum of 10 mg once daily, carvedilol 25 mg twice daily (the COPERNICUS target, and the target dose in COMET, which compared it against metoprolol tartrate 50 mg twice daily), or metoprolol succinate started at 12.5 or 25 mg once daily and uptitrated to the MERIT-HF target of 200 mg once daily^{[5][17][18][20]}; nebivolol, titrated from 1.25 mg to 10 mg once daily, was studied in patients aged 70 or older (SENIORS).^[19] The cardinal rule is "start low, go slow" — initiate at a low dose (bisoprolol 1.25 mg once daily; carvedilol 3.125 mg twice daily) only once the patient is euvolaemic and haemodynamically stable, and uptitrate over the following weeks toward target.^[1]

Pillar 3 — Mineralocorticoid receptor antagonist (MRA)

Spironolactone 25 mg once daily in moderate-to-severe HF (the RALES regimen)^[6] or eplerenone, initiated at 25 mg and titrated to a maximum of 50 mg daily after MI with LV dysfunction (EPHESUS)^[21] or in mild symptomatic HFrEF (EMPHASIS-HF, up to 50 mg daily)^[7]. The MRA earns its pillar because it blocks the direct profibrotic effect of aldosterone on the myocardium. Monitor potassium and creatinine at baseline, after initiation (1 to 2 weeks), after every uptitration, and routinely — hyperkalaemia and a creatinine rise are the dose-limiting toxicities (a potassium above 5.5 mmol/L occurred in 11.8 percent on eplerenone versus 7.2 percent on placebo in EMPHASIS-HF, and serious hyperkalaemia in EPHESUS in 5.5 versus 3.9 percent). Spironolactone also causes gynaecomastia and breast tenderness — in RALES, 10 percent of treated men versus 1 percent on placebo — which is a reason to switch to eplerenone.^[7][21][6]

Pillar 4 — SGLT2 inhibitor

Dapagliflozin 10 mg once daily (DAPA-HF)^[8] or empagliflozin 10 mg once daily (EMPEROR-Reduced)^[9] — benefit regardless of diabetes status. SGLT2 inhibitors have proven outcome benefit in both HFrEF and HFpEF, making them the only pillar class with trial evidence across the ejection-fraction spectrum (EMPEROR-Preserved and DELIVER each reduced cardiovascular death or HF hospitalisation above an EF of 40 percent).^[10][11] They are well tolerated and need no dose titration. They cause volume depletion (an advantage when congested, a caution in a hypovolaemic patient) and a small genital infection risk.^[1]

^{[4] [17] [18] [5] [6] [21]}

Symptomatic therapy — the loop diuretic

A loop diuretic is given for symptom relief and decongestion but does not improve survival, and in the acutely congested patient the DOSE trial found no difference in the primary endpoints between IV bolus and continuous infusion, while the high-dose strategy decongested more effectively than low-dose without clinically important effects on renal function. It remains the first drug in the acutely congested patient and is continued at the lowest dose that keeps the patient euvolaemic. Diuretic resistance may respond to combination with a thiazide (e.g. metolazone) for sequential nephron blockade — but watch for over-diuresis, hypokalaemia, and renal impairment; where congestion persists despite maximal furosemide dosing, switching to torsemide improved NYHA class in meta-analysis without proven mortality or readmission benefit.^[16][27][1]

The named add-ons

• Ivabradine 5 to 7.5 mg twice daily (SHIFT) for patients in sinus rhythm with a heart rate of at least 70 bpm despite maximally tolerated beta-blocker and an LVEF of 35 percent or less — it selectively inhibits the SA node If current. It works only in sinus rhythm (the AV node, not the If current, controls rate in AF), and meta-analysis shows ivabradine-treated patients develop AF more often.^[12][25]
• Hydralazine plus isosorbide dinitrate as a fixed-dose combination (A-HeFT) added to standard therapy improved survival and reduced first hospitalisation in self-identified African-American patients with advanced HFrEF, and it remains an option when RAAS blockade cannot be used.^[13]
• Digoxin — for symptom control, especially in HFrEF with concomitant atrial fibrillation; the DIG trial showed it does not improve mortality but reduces overall and HF-related hospitalisation. Watch for toxicity (nausea, visual disturbance, arrhythmia), especially with hypokalaemia and renal impairment.^[23]
• Intravenous iron (ferric carboxymaltose) for iron deficiency (ferritin under 100 microgram/L, or 100 to 299 with transferrin saturation under 20 percent) — in FAIR-HF it improved symptoms and functional capacity irrespective of anaemia status.^[24]
• Anticoagulation is reserved for HF with concomitant AF, an LV thrombus, or another standard indication — routine anticoagulation in HF in sinus rhythm is not recommended.^[1]

Device therapy — CRT and ICD

^{[1] [35] [33]}

Sudden cardiac death from ventricular arrhythmia is a leading mode of death in HFrEF, and the ICD is the specific therapy that addresses it.^[1]

HFpEF and HFmrEF — what actually works

HFpEF management is comparatively limited: SGLT2 inhibitors are the only class with proven outcome benefit (EMPEROR-Preserved and DELIVER reduced HF hospitalisation and cardiovascular death).^[10][11] The rest is diuretics for congestion (furosemide or torsemide) plus aggressive control of the comorbidities that drive the syndrome — hypertension (optimal blood-pressure control is a class 1 recommendation), atrial fibrillation (rate and rhythm control), diabetes (SGLT2 inhibitors first-line; avoid thiazolidinediones, which retain fluid and are graded as harmful below an EF of 50 percent), obesity, and ischaemia. Classic HFrEF GDMT does not work in HFpEF and should not be reflexively applied.^[1][35]

In HFmrEF (EF 41 to 49), SGLT2 inhibitor benefit is established; the other three pillars are considered case by case, extrapolating from HFrEF. The closer the EF to 40, the stronger the case for full HFrEF-style GDMT.^[1]

The bedside phenotype — warm-and-wet versus cold-and-wet

A single clinical fork decides the acute therapy: is the patient warm or cold, wet or dry? Two questions, four quadrants.^[1]

• Warm and wet (well perfused, congested — the common decompensation): sit up, oxygen, IV loop diuretic, consider a nitrate infusion if hypertensive and free of RV infarct concerns, NIV if acidotic or distressed.
• Cold and wet, or cold and dry (hypoperfused — BP 80 systolic, cool mottled skin, lactate up): ICU, inotrope or vasopressor, urgent echo, stop pure vasodilators, consider the cardiogenic shock pathway — not more high-dose nitrate.^[1]

Specific reversible cardiomyopathies — name them, they recover

Several aetiologies deserve explicit naming because they are reversible or partially reversible with cause-directed therapy — examiners reward every one:^[1]

• Tachycardiomyopathy — chronic tachycardia (persistent AF, inappropriate sinus tachycardia, ectopic atrial tachycardia) produces a dilated, failing LV that recovers substantially once rate or rhythm is controlled.
• Peripartum cardiomyopathy — HF with LVEF 45 percent or less towards the end of pregnancy or in the months postpartum; treat with standard HFrEF GDMT (with pregnancy-specific caveats — avoid ACE-inhibitor, ARB, and MRA in pregnancy; bromocriptine has emerging evidence). May recover fully. Recurrence in a subsequent pregnancy is a real risk.
• Alcoholic cardiomyopathy — a dilated cardiomyopathy in chronic heavy drinkers; abstinence leads to substantial recovery in many.
• Anthracycline-induced cardiotoxicity (doxorubicin) and anti-HER2 therapy (trastuzumab) — increasingly common drug causes; anthracycline damage is cumulative and largely irreversible, trastuzumab often reversible on cessation. Baseline and surveillance echo are standard.
• Iron overload (haemochromatosis, repeated transfusions), thyroid dysfunction (both hyper- and hypothyroidism), selenium deficiency, thiamine deficiency (beriberi), and HIV-related cardiomyopathy — all treatable aetiologies to actively seek.^[1]

The four cardiomyopathy patterns an examiner expects: dilated (DCM — dilated LV, thin walls, commonest, often idiopathic, familial, or post-viral), hypertrophic (HCM — asymmetric septal hypertrophy, dynamic LVOT obstruction, diastolic dysfunction, sudden-death risk), restrictive (RCMP — stiff non-compliant ventricles, e.g. amyloidosis, eosinophilic), and arrhythmogenic RV cardiomyopathy (ARVC — fibrofatty RV replacement, ventricular arrhythmia, sudden death). HCM and amyloidosis predominantly cause HFpEF-like physiology; DCM predominantly causes HFrEF. Cardiac MRI with late gadolinium enhancement is the discriminating test.^[1]

How heart failure patients come to harm — the preventable list

• A beta-blocker started in a still-congested patient, ending in acute collapse — the preventable deterioration.^[1]
• All four HFrEF pillars applied to a patient with HFpEF, where only the SGLT2 inhibitor helps.^[1]
• A patient left indefinitely on sub-therapeutic starting doses, never titrated to target — the mortality benefit accrues to target dosing.^[1]
• A rising potassium or creatinine on RAAS or MRA ignored until it is dangerous — or, just as often, the drugs reflexively stopped for a small acceptable rise that should have been reassessed.^[1]
• The ACE-inhibitor-to-ARNI switch done without the 36-hour washout, ending in angioedema.^[1]
• An elevated BNP on ARNI read as "worsening HF" — BNP is falsely elevated; NT-proBNP is the marker.^[1]
• A decompensation decongested without ever identifying or treating the precipitant — guaranteeing early relapse and readmission.^[1]
• A cold, oliguric patient given more diuretic instead of inotropes.^[1]
• SGLT2 inhibitors underused, even though they work across the whole EF spectrum and with or without diabetes.^[1]

Prognosis, disposition, and the markers that matter

Despite modern GDMT, heart failure remains life-limiting: pooled five-year survival is about 57 percent, and outcomes are worse with advanced NYHA class, repeated hospitalisations, hyponatraemia, rising natriuretic peptides, declining eGFR, and right-ventricular failure. A single HF hospitalisation is a major prognostic event — in the Trivandrum Heart Failure Registry in-hospital mortality was 9.7 percent in HFrEF (4.8 percent in HFpEF), 44.8 percent had died by three years and 59 percent by five years — which is why discharge planning, GDMT optimisation, and early follow-up are examinable management steps, not afterthoughts.^[31][30][29]

^[1]

NYHA functional class (reproduce verbatim): I, no limitation of ordinary activity; II, slight limitation, comfortable at rest, ordinary activity causes symptoms; III, marked limitation, less-than-ordinary activity causes symptoms; IV, symptoms at rest.^[1]

ACC/AHA stages (complement NYHA — structure versus symptoms): A, at risk (hypertension, diabetes, CAD) without structural disease or symptoms; B, pre-HF, structural disease or raised NP or abnormal filling without current or prior symptoms; C, symptomatic HF, current or prior; D, advanced HF needing specialised interventions.^[1]

Safe discharge checklist

• Near euvolaemia (stable weight, resolving oedema, no resting dyspnoea).
• Stable vital signs off oxygen (or a stable home oxygen plan).
• Transitioned to oral diuretic with a clear, flexible dosing plan.
• GDMT started or continued — do not stop prognostic drugs for a mild creatinine or potassium rise without a cause.
• Electrolytes and renal function checked after any diuretic or RAAS change.
• Early follow-up within 7 to 14 days (phone or clinic) — the highest-risk window for readmission.
• Self-care education: daily weights, individualised salt and fluid advice, red-flag dyspnoea or oedema, medication adherence.
• Vaccinations (influenza, pneumococcal, COVID-19) and comorbidity optimisation (iron deficiency, sleep apnoea, thyroid, anaemia).^[1]

Advanced HF triggers for specialist referral: recurrent hospitalisations, persistent NYHA III to IV despite optimised GDMT, intolerance of GDMT from hypotension or renal limits, markedly reduced peak VO2, progressive end-organ dysfunction, or inotrope dependence — evaluate for transplant, LVAD, and palliative care in parallel, not sequentially and late.^[1]

Special populations

Elderly and frail. Balance prognostic drug benefit against hypotension, falls, CKD, cognitive impairment, and polypharmacy. Prefer once-daily regimens, start low and titrate slow, but do not deny SGLT2 inhibitors, beta-blockers, or MRAs solely for age. HFpEF physiology dominates in older women with hypertension and AF. Involve geriatric assessment when frailty is clear.^[1]

Chronic kidney disease. Some rise in urea, creatinine, and potassium is expected after starting an ACE-inhibitor, ARB, or ARNI; a creatinine rise of up to 50 percent above baseline (or to 266 micromol/L, whichever is the smaller) and a potassium up to 5.5 mmol/L are acceptable in a euvolaemic patient. Larger rises prompt a search for obstruction, over-diuresis, bilateral renal artery stenosis, or NSAIDs — halve the dose if potassium exceeds 5.5 mmol/L or creatinine reaches 221 micromol/L, and stop the drug if potassium exceeds 6.0 mmol/L or creatinine exceeds 310 micromol/L. Hyperkalaemia limits the MRA and ARNI — use dietary measures, diuretic adjustment, and potassium binders in selected patients rather than abandoning GDMT reflexively. SGLT2 inhibitors slow CKD progression (DAPA-CKD and EMPA-KIDNEY logic) and are foundational across the EF spectrum when eGFR allows. Avoid NSAIDs, dose-adjust renally cleared drugs, and watch digoxin levels.^[1]

Atrial fibrillation and HF. AF both causes and results from HF. Rate control (beta-blocker first line) is foundational; digoxin is a useful adjunct for rate in HFrEF. Rhythm control, including early AF ablation, may improve outcomes in selected HFrEF patients with AF (CASTLE-AF logic). Anticoagulate by CHA2DS2-VASc unless contraindicated — HF itself scores a point.^[1]

Diabetes and HF. SGLT2 inhibitors are first-line cardio-renal drugs in this overlap (DAPA-HF, EMPEROR-Reduced and -Preserved). Avoid thiazolidinediones (fluid retention). Metformin is generally safe in stable HF with adequate eGFR. Screen for silent ischaemia when the presentation is atypical.^[1]

Pregnancy and peripartum cardiomyopathy (PPCM). New HF in the last month of pregnancy or within 5 months postpartum without other cause means consider PPCM. Manage in a cardio-obstetric team: afterload reduction with hydralazine plus nitrate (ACE-inhibitor, ARB, and ARNI are contraindicated in pregnancy), a beta-blocker such as metoprolol if needed, diuretics for congestion, and anticoagulation for thrombus or AF. Bromocriptine is used in some protocols as disease-modifying therapy. Subsequent pregnancy risk is high if LVEF does not recover — counselling is mandatory.^[1]

Chemotherapy-related cardiac dysfunction. Anthracyclines and HER2-targeted therapy (trastuzumab) are the classics. Monitor LVEF, hold or adjust oncologic therapy with cardio-oncology input, and treat along HFrEF lines when systolic dysfunction appears.^[1]

Iron deficiency (even without anaemia). IV ferric carboxymaltose improves symptoms and reduces HF hospitalisations in iron-deficient HFrEF (AFFIRM-AHF and IRONMAN logic). Check ferritin and transferrin saturation in all symptomatic HF patients.^[1]

The trials behind each pillar — and the names that score

The framework rests on the 2023 Focused Update of the 2021 ESC Guidelines^[1] and the 2022 AHA/ACC/HFSA Guideline^[2]. Both converge on the same core: four foundational HFrEF therapies initiated together where tolerated, SGLT2 inhibitors across the entire EF spectrum, and diuretics reserved for symptom control.

^[1]

Current controversies to name calmly: the optimal sequencing of the four pillars when all cannot be started at once; whether vericiguat, omecamtiv mecarbil, and finerenone add incremental benefit; the persistent difficulty of treating HFpEF beyond SGLT2 inhibitors and comorbidity control; and whether LVEF is a continuous or categorical variable (the "recovered EF" group sits ambiguously between HFrEF and HFpEF).^[1]

The mantra, and the target doses

Target doses of foundational HFrEF therapy — the high-yield table:^[1]

^{[1] [3] [22] [17] [18] [5] [21] [7] [26] [16]}

Worked stem — the creatinine that rose 20 percent after enalapril. If the patient is euvolaemic, not hyperkalaemic, and the rise is under 50 percent of baseline, continue and recheck — RAAS blockade saves lives. If the potassium rises above 5.5 mmol/L (or creatinine reaches 221 micromol/L), halve the dose and recheck within 1 to 2 weeks; if the potassium exceeds 6.0 mmol/L or the creatinine more than doubles, stop the drug, reassess volume, exclude obstruction, NSAIDs, and bilateral renal artery stenosis, and seek specialist advice.^[1]

Worked stems, rapid:^[1]

1. Warm and wet hypertensive pulmonary oedema — sit up, oxygen, an IV loop diuretic bolus, nitrates if BP allows, NIV.^[1]
2. Cold and wet, BP 80 systolic — shock pathway; stop pure vasodilators; inotrope and ICU; urgent echo.
3. HFrEF discharge meds — ARNI or ACE-inhibitor plus evidence-based beta-blocker plus MRA plus SGLT2 inhibitor, with or without a diuretic; do not withhold all GDMT for a mild creatinine rise.
4. LVEF 30 percent, LBBB QRS 160 ms, NYHA III on GDMT — CRT-D evaluation.
5. Iron deficiency in HFrEF even without anaemia — IV iron improves symptoms and hospitalisations.
6. Peripartum dyspnoea plus a dilated LV — PPCM; no ACE-inhibitor in pregnancy; hydralazine and nitrate strategy.^[1]

The mantra: four pillars, started together, titrated to target — and never a beta-blocker in a wet patient.^[1]

Ward-round test — three stems, thirty seconds each

Stem 1 — the man from the top of the topic (answer)ShowHide

The 68-year-old sleeping upright with crackles, raised JVP, displaced apex, and an S3. What is your first ten minutes, and what is the one drug you must NOT start today? Model: This is acute pulmonary oedema, likely HFrEF given the S3. First ten minutes: sit him upright, give oxygen to correct hypoxia, an IV furosemide bolus, an IV nitrate if his blood pressure permits, and CPAP if he remains distressed — while sending bloods, ECG, troponin, NT-proBNP, and an urgent echo, and hunting the precipitant (AF, ischaemia, non-adherence, infection). The one drug you must not start today is a beta-blocker — he is congested and decompensated, and a negative inotrope now could collapse him. Decongest first, confirm stability, then start low and titrate slow.^[1]

Stem 2 — the cold and wet patient (answer)ShowHide

Known HFrEF, now dyspnoeic with BP 80/50, cool mottled skin, lactate 4, and a faint pulse. The registrar plans more furosemide and a GTN infusion. Correct them. Model: This is cardiogenic shock, not pulmonary oedema — cold and wet, not warm and wet. More diuretic and a vasodilator will drop his pressure further. Stop pure vasodilators, move him to ICU, start an inotrope (dobutamine) with a vasopressor (noradrenaline) as needed, get an urgent echo for a mechanical or ischaemic cause, and pursue cause-directed therapy (revascularisation, valve intervention, mechanical circulatory support). Routine IABP is not indicated.^[1]

Stem 3 — the discharge prescription (answer)ShowHide

A 60-year-old with a new LVEF of 30 percent is ready for discharge after a decompensation. What does her prescription contain, and what follow-up must you book? Model: All four pillars, started at low dose and with a written uptitration plan to target: ARNI (or an ACE-inhibitor if ARNI is unavailable, with a 36-hour washout if switching) — sacubitril/valsartan toward 97/103 mg BD; an evidence-based beta-blocker such as bisoprolol toward 10 mg OD, now that she is euvolaemic; an MRA, spironolactone 25 mg OD (eplerenone up to 50 mg OD) with potassium and creatinine checked at 1 to 2 weeks; and a SGLT2 inhibitor, dapagliflozin 10 mg OD. Add a loop diuretic at the lowest dose that keeps her euvolaemic, check iron studies and treat deficiency, and arrange cardiac rehabilitation and early follow-up within 7 to 14 days — the highest-risk window for readmission.^{[1][17][21][24]}

References37ShowHide

1. [1]McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Eur Heart J, 2023.PMID 37622666
2. [2]Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines J Am Coll Cardiol, 2022.PMID 35379503
3. [3]CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) N Engl J Med, 1987.PMID 2883575
4. [4]McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure N Engl J Med, 2014.PMID 25176015
5. [5]MERIT-HF Study Group Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet, 1999.PMID 10376614
6. [6]Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med, 1999.PMID 10471456
7. [7]Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med, 2011.PMID 21073363
8. [8]McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction N Engl J Med, 2019.PMID 31535829
9. [9]Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure N Engl J Med, 2020.PMID 32865377
10. [10]Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction N Engl J Med, 2021.PMID 34449189
11. [11]Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction N Engl J Med, 2022.PMID 36027570
12. [12]Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study Lancet, 2010.PMID 20801500
13. [13]Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure N Engl J Med, 2004.PMID 15533851
14. [14]Peacock WF, Hollander JE, Diercks DB, et al. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis Emerg Med J, 2008.PMID 18356349
15. [15]Winck JC, Azevedo LF, Costa-Pereira A, et al. Efficacy and safety of non-invasive ventilation in the treatment of acute cardiogenic pulmonary edema--a systematic review and meta-analysis Crit Care, 2006.PMID 16646987
16. [16]Campbell PT, Ryan J. Diuretic dosing in acute decompensated heart failure: lessons from DOSE Curr Heart Fail Rep, 2012.PMID 22699924
17. [17]CIBIS-II Investigators The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial Lancet, 1999.PMID 10023943
18. [18]Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure N Engl J Med, 2001.PMID 11386263
19. [19]Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) Eur Heart J, 2005.PMID 15642700
20. [20]Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial Lancet, 2003.PMID 12853193
21. [21]Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med, 2003.PMID 12668699
22. [22]Yusuf S, Pitt B, Davis CE, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med, 1991.PMID 2057034
23. [23]Digitalis Investigation Group The effect of digoxin on mortality and morbidity in patients with heart failure N Engl J Med, 1997.PMID 9036306
24. [24]Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency N Engl J Med, 2009.PMID 19920054
25. [25]Martin RI, Pogoryelova O, Koref MS, et al. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials Heart, 2014.PMID 24951486
26. [26]Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial Lancet, 2003.PMID 13678870
27. [27]Kido K, Shimizu M, Hashiguchi M. Comparing torsemide versus furosemide in patients with heart failure: A meta-analysis J Am Pharm Assoc (2003), 2019.PMID 30846351
28. [28]Harikrishnan S, Rath PC, Bang V, et al. Heart failure, the global pandemic: A call to action consensus statement from the global presidential conclave at the platinum jubilee conference of cardiological society of India 2023 Indian Heart J, 2024.PMID 38609052
29. [29]Harikrishnan S, Jeemon P, Ganapathi S, et al. Five-year mortality and readmission rates in patients with heart failure in India: Results from the Trivandrum heart failure registry Int J Cardiol, 2021.PMID 33049297
30. [30]Sanjay G, Jeemon P, Agarwal A, et al. In-Hospital and Three-Year Outcomes of Heart Failure Patients in South India: The Trivandrum Heart Failure Registry J Card Fail, 2018.PMID 29885494
31. [31]Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure Eur J Heart Fail, 2020.PMID 32483830
32. [32]van Riet EE, Hoes AW, Wagenaar KP, et al. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review Eur J Heart Fail, 2016.PMID 26727047
33. [33]Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure N Engl J Med, 2005.PMID 15659722
34. [34]Joshi PP, Mohanan CJ, Sengupta SP, et al. Factors precipitating congestive heart failure--role of patient non-compliance J Assoc Physicians India, 1999.PMID 10999123
35. [35]Behnoush AH, Khalaji A, Naderi N, et al. ACC/AHA/HFSA 2022 and ESC 2021 guidelines on heart failure comparison ESC Heart Fail, 2023.PMID 36460629
36. [36]National Institute for Health and Care Excellence Chronic heart failure in adults: diagnosis and management NICE NG106, 2018.Source
37. [37]National Institute for Health and Care Excellence Acute heart failure: diagnosis and management NICE CG187, 2014.Source